Philippe Meresse
Curie Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Philippe Meresse.
Current Medicinal Chemistry | 2004
Philippe Meresse; Elsa Dechaux; Claude Monneret; Emmanuel Bertounesque
Etoposide is an antitumor agent currently in clinical use for the treatment of small cell lung cancer, testicular cancer and lymphomas. Since the introduction of etoposide in 1971, its mechanism of action and potent antineoplastic activity has served as the impetus for intensive research activities in chemistry and biology. This drug acts by stabilizing a normally transient DNA-topoisomerase II complex, thus increasing the concentration of double-stranded DNA breaks. This phenomenon triggers mutagenic and cell death pathways. The function of topoisomerase II is understood in some detail, as is the mechanism of inhibition of etoposide at a molecular level. Etoposide has shortcomings of limited neoplastic activity against several solid tumors such as non-small cell lung cancer, cross-resistance to MDR tumor cell lines and low bioavailability. The design and synthesis of etoposide analogs is an activity of fundamental interest to the field of cancer chemotherapy. In the first part, this article is a survey of the discovery of etoposide, the DNA topoisomerase II structure and mechanism, and the models for drug-enzyme interaction. The last part is concerned with the search for new etoposide analogs based upon an empirical design.
Tetrahedron Letters | 1997
Laurent Daley; Philippe Meresse; Emmanuel Bertounesque; Claude Monneret
Abstract One-pot syntheses of 4′-demethylepipodophyllotoxin 7 and NPF 2 (4′- O -demethyl-4β-(4″-fluoroanilino)-4-deoxypodophyllotoxin) are described from podophyllotoxin 3 via a protocol using trimethylsilyl iodide in 72% and 52% overall yields, respectively.
Tetrahedron | 1999
Philippe Meresse; Emmanuel Bertounesque; Thierry Imbert; Claude Monneret
The studies feature the transformation of etoposide 1 into the pivotal intermediate (+)-19 for the elaboration of pyridazine-fused aromatic systems via a Stille cross-coupling. The synthesis of A-ring pyridazine picroetopiside (+)-21 has been achieved in 11 steps.
Tetrahedron-asymmetry | 1998
Emmanuel Bertounesque; Fatima Millal; Philippe Meresse; Claude Monneret
Abstract The synthesis of non racemic chiral γ-lactone 7 from α-D-isosaccharino-1,4-lactone (+)- 8 , as a precursor of the A-ring of the targeted 3′-morpholinyl-9-pentyl anthracycline 6 , is described.
Journal of Medicinal Chemistry | 2005
Maria Duca; Dominique Guianvarc'h; Philippe Meresse; Emmanuel Bertounesque; Daniel Dauzonne; Laurence Kraus-Berthier; Sylvie Thirot; Stephane Leonce; Alain Pierré; Bruno Pfeiffer; Pierre Renard; Paola B. Arimondo; Claude Monneret
Tetrahedron | 2004
Philippe Meresse; Claude Monneret; Emmanuel Bertounesque
Archive | 2001
Claude Monneret; Emmanuel Bertounesque; Philippe Meresse; Ghanem Atassi; Alain Pierre; John Hickman; Bruno Pfeiffer; Pierre Renard
Tetrahedron Letters | 2007
Emmanuel Bertounesque; Philippe Meresse; Claude Monneret; Jean-Claude Florent
Bioorganic & Medicinal Chemistry Letters | 2003
Philippe Meresse; Prokopios Magiatis; Emmanuel Bertounesque; Claude Monneret
Archive | 2001
Claude Monneret; Emmanuel Bertounesque; Philippe Meresse; Ghanem Atassi; Alain Pierre; Bruno Pfeiffer; Pierre Renard